VERTEX PHARMACEUTICALS INC / MA — Director's Dealing 2021

Feb 19, 2021

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: VERTEX PHARMACEUTICALS INC / MA (VRTX)
CIK: 0000875320
Period of Report: 2021-02-17

Reporting Person: Parini Michael (EVP, Chief Adm, Leg & BD Off)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2021-02-17	Common Stock	F	6240	$211.75	Disposed	44106	Direct
2021-02-18	Common Stock	S	1007	$210.08	Disposed	43099	Direct
2021-02-18	Common Stock	S	4666	$211.83	Disposed	38433	Direct
2021-02-18	Common Stock	S	1952	$212.56	Disposed	36481	Direct
2021-02-18	Common Stock	S	200	$213.45	Disposed	36281	Direct

Footnotes

F1: Transaction made pursuant to Mr. Parini's company-approved trading plan under Rule 10b5-1.

F2: Open market sales reported on this line occurred at a weighted average price of $210.08 (range $209.60 to $210.54).

F3: Mr. Parini undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price.

F4: Open market sales reported on this line occurred at a weighted average price of $211.83 (range $211.25 to $212.24).

F5: Open market sales reported on this line occurred at a weighted average price of $212.56 (range $212.25 to $212.95).

F6: Open market sales reported on this line occurred at a weighted average price of $213.45 (range $213.30 to $213.68).